Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.34 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1728237 | 0.76 | DPP4 (0.77) | DPP4F2 | |
| SCHEMBL6034367 | 0.70 | PREP (0.38) | DPP4 | |
| SCHEMBL6034365 | 0.70 | PREP (0.38) | DPP4 | |
| Trifluoroacetic Acid SCHEMBL33525765 | 0.65 | CYP3A4 (0.38) | DPP4DPP8F2 | |
| Trifluoroacetic Acid SCHEMBL23671375 | 0.62 | DPP4 (0.35) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL16818579 | 0.62 | DPP4 (0.35) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL16818510 | 0.62 | DPP4 (0.35) | DPP4DPP8 | |
| SCHEMBL17775468 | 0.62 | CYP3A4 (0.36) | DPP4 | |
| Trifluoroacetic Acid SCHEMBL31630320 | 0.62 | DPP4 (0.33) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3899456 | 0.62 | DPP4 (0.33) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651649-B1 | NOVEL CYANOPYRROLIDIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-7094800-B2 | pyrrolizinones, e.g., (3S,6R,7aS)-6-amino-5-oxo-hexahydro-pyrrolizine-3-carbonitrile trifluoroacetate, used for reducing blood sugar, treating type 2 diabetes, and treating insulin resistance | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-08-22 | — | — | US | disclosed |
| EP-1651649-A1 | NOVEL CYANOPYRROLIDIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
| WO-2005012308-A1 | NOVEL CYANOPYRROLIDIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | CYP11B2, SLC5A2, CYP11B1 | DPP4 122/4885DPP8 892/4885F2 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.